Altimmune (NASDAQ:ALT) Trading Up 16.1% – Time to Buy?

Altimmune, Inc. (NASDAQ:ALT)’s stock price shot up 16.1% on Friday . The stock traded as high as $5.94 and last traded at $6.2470. 2,101,752 shares were traded during trading, a decline of 62% from the average session volume of 5,556,123 shares. The stock had previously closed at $5.38.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ALT shares. Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Citizens Jmp reduced their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Altimmune currently has an average rating of “Hold” and a consensus target price of $16.60.

Altimmune Stock Up 2.2%

The stock has a market capitalization of $573.87 million, a price-to-earnings ratio of -5.14 and a beta of 0.04. The firm has a 50 day simple moving average of $4.57 and a 200-day simple moving average of $4.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, sell-side analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Insider Activity

In other news, Director Jerome Benedict Durso acquired 12,500 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of $4.13 per share, with a total value of $51,625.00. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at $51,625. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Gill bought 12,500 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 30,527 shares of company stock worth $125,278 over the last ninety days. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of Altimmune by 13.4% during the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares during the last quarter. Brown Wealth Management LLC lifted its holdings in Altimmune by 131.0% during the 2nd quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock worth $894,000 after buying an additional 131,059 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Altimmune by 102.9% during the 2nd quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock worth $561,000 after buying an additional 73,482 shares in the last quarter. Moody Aldrich Partners LLC bought a new position in Altimmune in the 2nd quarter valued at $610,000. Finally, Concurrent Investment Advisors LLC increased its stake in shares of Altimmune by 16.4% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 25,258 shares of the company’s stock valued at $98,000 after buying an additional 3,565 shares during the period. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.